Jazz Pharma Reports Positive Topline Data From Phase 3 IMforte Maintenance Study In ES-SCLC
I'm PortAI, I can summarize articles.
Jazz Pharmaceuticals plc (JAZZ) announced positive top-line results from the Phase 3 IMforte study for adults with extensive-stage small cell lung cancer (ES-SCLC). The study evaluated the combination of Zepzelca and atezolizumab, showing significant improvements in overall survival and progression-free survival compared to atezolizumab alone. The combination was well tolerated, with no new safety signals. Jazz plans to submit a supplemental New Drug Application in the first half of 2025 for this combination therapy as a first-line maintenance treatment for ES-SCLC.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments